PureTech declares mid-stage trial win for pulmonary fibrosis drug

Katherine Lewin

News Reporter

PureTech Health unveiled positive Phase 2b data on Monday for its idiopathic pulmonary fibrosis drug, which showed it can reduce lung function decline in patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PureTech declares mid-stage trial win for pulmonary fibrosis drug

Katherine Lewin

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company

Purdue, Sacklers reach new $7.4B opioid settlement after SCOTUS rejection

As another Trump term gets underway, pharma advisors get comfortable with uncertainty

China's biotech boom is threatening US drugmakers' dominance

AbbVie partners with Neomorph in latest molecular glue deal

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

PureTech de­clares mid-stage tri­al win for pul­monary fi­bro­sis drug

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

PureTech declares mid-stage trial win for pulmonary fibrosis drug